Another Covidien shareholder sues to block the pending, $43 billion merger with Medtronic, arguing that the deal violates both American and Irish laws.
The terms of Medtronic's unusual $43 billion acquisition of Covidien means that all MDT shareholders are subject to paying a capital gains tax, including executives and board members.
Medtronic engages former Senators Trent Lott and John Breaux to lobby on behalf of the company's $43 billion acquisition of Covidien and its subsequent move overseas.
Medtech titan Medtronic (NYSE:MDT) has a few heavy-hitters in its corner during its fight against anti-corporate inversion measures on Capitol Hill.
Despite the furor on Capitol Hill, lawmakers aren't likely to produce reform that will hinder Medtronic's $43 billion acquisition of Covidien, according to Morgan Stanley analysts.
Here's a look at some of the top regulatory stories for medical device companies this week: Report: Medtech M&A exits don't hinge on FDA approval; White House rails against Medtronic-style corporate inversions; Smith & Nephew CEO: We've been an M&A target for 10 years; More mega-merger talk from medtech giants; Baxter sheds vaccines biz for $635M
Covidien discloses details of the pending $43 billion acquisition by Medtronic, including who approached who and what Covidien chief Jose Almeida will do after handing the reins to Medtronic.
Democrats in the Senate and House push a measure to withhold federal contracts from companies that move their headquarters overseas to find better corporate tax rates.
A handful of Democrats in Congress are hoping to curb a corporate exodus by threatening to withhold federal contracts from firms that shift their headquarters overseas to benefit from lower tax rates.